News

3P Biopharmaceuticals awards prize for the best Final Degree Project in Pharmacy at the University of Navarra

Published: 24th June 2022
The award forms part of an agreement between 3P and the Faculty of Pharmacy at the University of Navarra promoting digital transformation and professional training within the pharmaceutical industry.
Read more

3P Biopharmaceuticals makes a significant donation to help Ukraine

Published: 18th March 2022
3P Biopharmaceuticals, a leading organization specializing in the development of cGMP processes and manufacturing of biological products (CDMO) makes financial and material donations to help Ukraine.
Read more

Dámaso Molero, appointed member of the Technical Committee of the Interdepartmental Commission for Personalized Medicine of Navarra.

Published: 4th March 2022
3P Biopharmaceuticals, a leading organization specializing in the development of cGMP processes and manufacturing of biological products (CDMO), is part of the Technical Committee of the Interdepartmental Commission for Personalized Medicine of Navarra.
Read more

3P Biopharmaceuticals appoints Ricardo Izquierdo as Quality Director

Published: 11th February 2022
3P Biopharmaceuticals appoints a new member to the management team with the incorporation of Ricardo Izquierdo as Quality Director.
Read more

Osivax and 3P Biopharmaceuticals team up to develop a new universal vaccine against current and future variants of SARS-COV-2

Published: 26th November 2022
Osivax's novel oligoDOM® technology, designed to induce potent T-cell responses, will serve as the basis for this broad-spectrum vaccine against COVID-19
Read more

Elena Erroba, winner of the Navarra 2021 Management Award organised by AMEDNA-NEEZE

Published: 17th November 2022
Elena Erroba, Director of Business Development, Communication and Marketing at 3P Biopharmaceuticals, has been elected as Navarra’s Businesswoman of the Year 2021
Read more

3P Biopharmaceuticals presents its growth plan at BIOSPAIN to further expand its operations in Europe and the USA

Published: 29th September 2021
The investments will enable the company to increase its mammalian cell-based protein production capacity tenfold and increase its microbial cell-based protein production capacity by 50%. The total floor space of the company will triple.
Read more

3P Biopharmaceuticals enters into alliance with Precirix to develop precision radiopharmaceuticals in oncology

Published: 17th August 2021
3P Biopharmaceuticals and Precirix NV have signed an agreement for the clinical manufacturing of a camelid single-domain antibody fragment (sdAb), the backbone of Precirix’ next product candidate to enter the clinic.
Read more

3P Biopharmaceuticals receives FDA approval

Published: 5th July 2021
The FDA classified 3P facilities as acceptable for the manufacture of the target molecule, and appropriate for its commercialization in the US market, once the product is authorized
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.